Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide vs Yohimbine: Semaglutide has the stronger overall evidence (8.5 vs 5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Semaglutide and Yohimbine have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
Standardized yohimbine HCl ~0.2 mg/kg (roughly 5-15 mg) up to 1-2x daily; start at the lowest dose, ideally fasted for the fat-loss effect. Never combine with other stimulants.
morning
Standardized yohimbine HCl (known dose)
and 2 more not shown
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
3-8 weeks
2-8 weeks
Acute
Acute
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials.
The Journal of urology (1998) · Meta analysis
Meta-analysis of seven placebo-controlled RCTs of yohimbine monotherapy for erectile dysfunction
Yohimbine as a treatment for erectile dysfunction: A systematic review and meta-analysis.
Turkish journal of urology (2021) · Meta analysis
Systematic review and meta-analysis of eight RCTs comparing yohimbine to placebo for ED
Yohimbine: the effects on body composition and exercise performance in soccer players.
Research in sports medicine (2006) · Rct · n=20
Randomized placebo-controlled trial in 20 elite male soccer players, 20 mg/day for 21 days
Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.
For manage weight, Semaglutide has a higher relevance score (88 vs 55).
No known interactions between Semaglutide and Yohimbine have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.